Clinical Trials for HIV

385 hiv trials indexed, 135 currently recruiting. Updated daily from ClinicalTrials.gov.

Understanding HIV

HIV stands for Human Immunodeficiency Virus. It is a virus that attacks the body’s immune system, specifically the CD4 cells (T cells), which help fight infections. If untreated, HIV reduces the number of these cells, making the body more vulnerable to infections and certain cancers. The virus is mainly spread through contact with infected bodily fluids such as blood, semen, vaginal fluids, and breast milk. Diagnosis typically involves blood tests that detect either the virus itself or antibodies produced in response to the infection. Early diagnosis is important to manage the condition and prevent progression to AIDS (Acquired Immunodeficiency Syndrome).

Common symptoms of HIV can vary depending on the stage of infection. During the initial weeks after infection, some people experience flu-like symptoms such as fever, sore throat, and fatigue. After this acute phase, the virus may not cause noticeable symptoms for years. Without treatment, HIV gradually weakens the immune system, leading to opportunistic infections. HIV can affect people of any age, but it is most commonly diagnosed in adults aged 25 to 44. Certain groups face higher risks, including men who have sex with men, people who inject drugs, and individuals in regions with high prevalence rates. Risk factors also include unprotected sex and having multiple sexual partners.

HIV remains a significant medical and social challenge worldwide. According to the World Health Organization, approximately 38 million people were living with HIV globally in recent years. In the United States alone, about 1.2 million people have HIV. The virus not only affects individual health but also carries a substantial economic burden, with healthcare costs and lost productivity reaching billions annually. Social stigma and discrimination linked to HIV can also impact the quality of life and access to care for many affected individuals. Understanding HIV is key to controlling its spread and improving outcomes for those living with the virus.

The HIV Treatment Landscape

The first-line standard of care for HIV involves antiretroviral therapy (ART), which uses a combination of drugs to suppress the virus and stop disease progression. The goal of ART is to reduce the viral load to undetectable levels, helping the immune system recover and preventing transmission. Treatment usually starts with a regimen that includes two nucleoside reverse transcriptase inhibitors (NRTIs) paired with a third drug from another class. This approach is recommended by health authorities such as the U.S. Department of Health and Human Services and is adjusted based on individual patient needs and drug tolerability.

When first-line treatments are not effective or cause intolerable side effects, second- and third-line options are considered. These include drugs from different classes such as protease inhibitors (PIs), integrase strand transfer inhibitors (INSTIs), and entry inhibitors. Examples of established drugs include efavirenz (an NNRTI), darunavir (a PI), and dolutegravir (an INSTI). Physicians may switch regimens to address drug resistance or to reduce side effects. The availability of multiple drug classes allows for personalized treatment plans that can adapt to the virus’s changing behavior and patient response.

Despite advances in ART, gaps remain in HIV treatment. Some people experience drug resistance, which limits their options and complicates management. Side effects from medications, such as gastrointestinal issues or metabolic changes, can reduce adherence to therapy. Certain subgroups, including individuals with co-existing conditions like tuberculosis or hepatitis, may respond poorly to standard treatments. Research is ongoing to develop drugs with fewer side effects, longer dosing intervals, and new mechanisms of action. Trials also explore strategies to address viral reservoirs and improve outcomes for those with drug-resistant HIV.

Why Clinical Trials Matter for HIV

Clinical trials play an important role in advancing HIV treatment and care. Patients who participate may gain access to new therapies not yet widely available. Trials often provide closer medical monitoring and support than standard care. By joining a study, participants contribute valuable data that helps researchers understand how well treatments work and how safe they are. ClinicalTrials.gov currently indexes about 385 HIV-related clinical trials, with around 135 actively recruiting participants. This range of studies covers prevention, treatment, and management strategies, offering options for many people affected by HIV.

Joining a clinical trial also involves certain risks. New treatments may have unknown side effects or may not prove effective. Some studies include placebo groups, meaning participants might not receive the active drug. Additional clinic visits, blood tests, or procedures may be required, which can be time-consuming or inconvenient. It is important for potential participants to discuss these factors with their healthcare provider and the research team to make informed decisions about enrollment.

The landscape of HIV clinical trials includes sponsors from different sectors. Academic institutions conduct many studies to explore scientific questions and improve care. Pharmaceutical companies develop and test new drugs to bring them to market. Cooperative groups often run large multi-center trials to gather robust data. ClinicalTrials.gov serves as a public registry that provides detailed information on these studies, helping patients and caregivers find trials that match their needs. This transparency supports informed participation and advances research efforts worldwide.

What to Look for in a HIV Clinical Trial

Clinical trials are typically divided into four phases. Phase 1 trials test a new treatment in a small group of people to evaluate safety and dosage. Phase 2 trials involve more participants to assess effectiveness and side effects. Phase 3 trials compare the new treatment to the current standard treatment in larger groups. Phase 4 trials happen after approval to monitor long-term effects. For HIV clinical trials, the distribution is as follows: 174 trials have no phase listed, 61 are in Phase 2, 54 in Phase 1, and 21 in Phase 3. Phase 2 is the most common phase for HIV studies.

When looking at inclusion criteria for HIV trials, several factors are important. Age limits often apply, typically including adults 18 years or older. Some trials require participants to have a specific history of HIV treatment, such as prior antiretroviral therapy or treatment-naive status. Biomarkers like viral load and CD4 cell count may also be considered. Trials may focus on certain stages of HIV infection or require a minimum duration since diagnosis. These criteria help ensure the study population matches the research goals.

Exclusion criteria are equally important and often relate to safety. Participants with other serious health conditions, such as liver or kidney disease, might be excluded to avoid complications. Drug interactions are another concern, so people taking certain medications may not qualify. Some trials set thresholds for blood pressure, heart rate, or lab values to reduce risks. These rules protect participants and help produce clear results by limiting confounding factors.

From a practical standpoint, patients should consider the length of the trial and the number of required visits. Some studies last several months or years and may need frequent clinic appointments. Travel distance and costs can be barriers for many people. Before enrolling, ask the research team these questions: How long will the trial last? What are the visit schedules and procedures? Are there any costs or reimbursements for travel? What happens if I decide to leave the trial early? Understanding these details helps patients make informed decisions about participation.

Primary Sources and Further Reading

For those interested in learning more about HIV clinical trials and related information, trusted sources offer detailed and up-to-date content. These websites provide guidance on HIV treatment, prevention, and research efforts. They are useful for patients, caregivers, and anyone seeking reliable health information.

Latest Research and Emerging Treatments for HIV (2026)

Recent HIV research is exploring new drugs that could change how people prevent and manage HIV infection. One promising option is MK-8527, a once-monthly pill being tested in several Phase 3 trials (NCT07071623, NCT07044297). This drug aims to prevent HIV-1 infection by blocking the virus early in its cycle. Unlike current daily pills, MK-8527 could offer a more convenient way to stay protected, which might help people stick to their prevention plan better. These studies include participants in Africa and globally, focusing on both women and people at risk of HIV-1 infection.

Another area of research involves lenacapavir, studied alongside emtricitabine/tenofovir alafenamide in adolescent girls and young women (NCT04994509). Lenacapavir works differently by targeting the virus’s ability to assemble and mature. It is available as an oral pill or a subcutaneous injection, which may reduce how often someone needs to take medication. This could simplify HIV prevention and improve daily life for those at risk. Although this study is active, it is not recruiting new participants currently.

For people living with HIV, new treatment options are also under study. One trial is testing a combination pill of doravirine and islatravir (NCT04223791) for those who already have their virus under control. Doravirine belongs to a class of drugs that block the virus’s ability to copy its genetic material, while islatravir is a newer drug that may work by stopping the virus from multiplying. This treatment could offer fewer side effects or simpler dosing compared to current options. Another study is exploring whether taking antiretroviral drugs four days a week is as effective as daily treatment (NCT03256422). If successful, this approach might reduce side effects and improve quality of life for people managing HIV.

Frequently asked questions about HIV trials

How do I find HIV clinical trials?

The authoritative source for HIV clinical trials is ClinicalTrials.gov, maintained by the U.S. National Library of Medicine. 385 hiv studies are currently indexed. You can search by entering "hiv" as the condition, then filter by recruiting status, phase, and location. TrialsAlert scans ClinicalTrials.gov daily for new hiv trials and delivers a plain-language briefing every Friday explaining what changed.

What phase are most HIV trials in?

Across the 385 hiv trials TrialsAlert indexes, the most common phase is Phase 2. Early-phase studies (Phase 1 and Phase 2) test safety and initial efficacy. Phase 3 trials compare a candidate treatment against the current standard of care in larger populations and generate the evidence regulators use to approve new therapies.

How many HIV clinical trials are currently recruiting?

As of the latest scan, 135 hiv trials have a "Recruiting" status on ClinicalTrials.gov, out of 385 total indexed. The recruiting figure changes daily as studies open, fill enrollment, and close. TrialsAlert subscribers are notified when a new recruiting hiv trial matches their tracked condition.

Stay informed about hiv research

Get a weekly briefing with the trials that matter most.

Start monitoring hiv trials